Loading...
•
Dec 31, 2023
Dyne Therapeutics Q4 2023 Earnings Report
Reported financial results for the fourth quarter and full year 2023 and recent business highlights.
Key Takeaways
Dyne Therapeutics reported positive initial clinical data from ACHIEVE and DELIVER trials, demonstrating proof-of-concept for their FORCE™ platform. They strengthened their balance sheet with a $345 million public offering, extending their cash runway through 2025. The company is focused on optimizing dose and dose regimen in 2024 and plans to provide updates from both trials in the second half of the year.
Reported positive initial clinical data from the ACHIEVE trial in DM1 patients.
Reported positive initial clinical data from the DELIVER trial in DMD patients.
Completed a $345 million public offering, extending projected cash runway through 2025.
Plan to report data from multiple, higher dose cohorts from both the ACHIEVE and the DELIVER trials in the second half of 2024.
Dyne Therapeutics
Dyne Therapeutics
Forward Guidance
Dyne anticipates reporting data from multiple, higher dose cohorts from both the ACHIEVE and the DELIVER trials in the second half of 2024 with the goal of initiating registrational cohorts by the end of 2024.